Mounjaro Injection 5mg: the First Dose Step That Actually Works

Step 1: how you get to 5mg (and why the sequence is deliberate)

Mounjaro is designed to be started at 2.5mg, a tolerability dose whose main job is helping your body adjust to a dual GIP and GLP-1 receptor agonist before any meaningful weight-loss effect is pursued. After roughly four weeks at 2.5mg, most people move up. If you want to understand that earlier part of the journey, the page on Mounjaro 2.5mg covers it in detail.

The 5mg injection is the next step. It is not a large jump in absolute terms, but for many people it is the rung where appetite suppression becomes properly felt — meals feel smaller before they are finished, and the background urge to snack reduces. That is consistent with how tirzepatide works: it activates receptors involved in satiety signalling and slows gastric emptying, so food stays in the stomach longer and fullness signals reach the brain sooner.

The sequence matters because titrating too quickly tends to worsen gastrointestinal side effects without improving results. The phased schedule (roughly four weeks at each level) is the approach the licensed prescribing information follows, and your prescriber works within that framework. They may recommend staying at 5mg for longer than one month if your body is still settling, or if your progress is steady and there is no clinical case yet for going higher. Worth knowing before you assume the schedule is automatic.

Step 2: using the 5mg pen, the practical things that help

Mounjaro is supplied as a pre-filled KwikPen. The 5mg pen contains four weekly doses; each week you dial and inject once, rotating between the abdomen, front of the thigh, and outer upper arm. Rotating sites matters, using the same spot repeatedly can affect absorption and cause localised reactions.

Injection day is worth anchoring to a routine. A lot of people pick the same day of the week and link it to something already fixed, some keep the pen in the fridge door next to the milk and inject on Sunday mornings before anything else. The NHS medicines page for tirzepatide covers the injection technique and storage requirements if you want the full detail; the Patient Information Leaflet inside the box is the definitive reference for exact timings and temperatures.

One practical note: if you are switching from 2.5mg to 5mg, you are moving to a new pen. The pen itself looks identical; check the strength label before injecting. That is not a minor point, it is the kind of thing our prescribers flag explicitly during clinical review, because mix-ups do occasionally happen when people are managing multiple pens.

Step 3: what the evidence says about 5mg as part of the full programme

The licensed trial data for Mounjaro as a whole comes primarily from the SURMOUNT-1 study, which enrolled around 2,500 adults with obesity over 72 weeks and tested multiple doses including 5mg. The programme demonstrated average weight reductions ranging from roughly 15% at lower maintenance doses up to around 20–21% at the highest, depending on the dose reached. The 5mg level is a transitional dose rather than a maintenance endpoint for most people, the expectation is continued titration unless there is a clinical reason to stay.

NICE reviewed the full evidence base when it recommended tirzepatide in December 2024 (NICE technology appraisal TA1026). The licensed eligibility for private treatment, which is what nume operates within, covers adults with a BMI of 30 or above, or 27 or above where at least one weight-related condition is present, things like high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. For a broader look at how the doses compare across the full range, the Mounjaro doses overview lays it out clearly.

A note on cost context: because dose affects the price of treatment in the private market, some people ask whether staying at 5mg for longer saves money. There is a Mounjaro price comparison page that explains how private pricing works across doses. The clinical answer is that dose decisions belong to your prescriber, not to your budget, results matter more than saving a month's cost at a lower strength.

Side effects to be aware of at the 5mg step

Gastrointestinal effects are the most commonly reported, nausea, loose stools, constipation, indigestion, and occasional burping. They tend to be most noticeable in the days after a dose increase and often settle within one to two weeks as the body adapts. Moving from 2.5mg to 5mg represents the first real therapeutic increase, so this is often when people first notice these effects in any meaningful way.

Eating smaller portions, avoiding high-fat meals around injection day, and staying well hydrated all help. If nausea is persistent or severe, that is a conversation for your prescriber rather than something to push through silently, they may suggest a slower titration or a longer period at the current dose.

The MHRA has also highlighted acute pancreatitis as a known but infrequent side effect of GLP-1 medicines. Severe, persistent stomach pain that radiates to the back (with or without vomiting) needs urgent medical attention, not a wait-and-see. Report any unexpected or persistent symptoms to your clinical team promptly. Side effects can also be reported via the MHRA Yellow Card scheme, which helps the regulator monitor safety signals across the wider population.

If you are considering where 5mg sits relative to the next steps, the pages on Mounjaro 7.5mg and Mounjaro 10mg cover those doses in the same detail. Your prescriber at nume reviews your progress clinically before any change is made, every repeat order is assessed afresh, not rolled over automatically.

Ready to get started or transfer your existing treatment? Start your free consultation and a GPhC-registered prescriber will review your details the same day.